NasdaqGS:TXGLife Sciences
Assessing 10x Genomics (TXG) Valuation After STELA Partnership And Ongoing Cathie Wood Buying
Why 10x Genomics Is Back in Focus
10x Genomics (TXG) is back on investor watchlists after two catalysts: its role in Bioptimus’ new STELA spatial tissue atlas, and steady share purchases by high profile fund manager Cathie Wood.
See our latest analysis for 10x Genomics.
The recent partnership on the STELA initiative and continued buying from Cathie Wood have arrived while the share price sits at US$20.43, with a 90 day share price return of 23.89% and a 1 year total shareholder return of...